MELINTA THERAPEUTICS
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, whic... h is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.
MELINTA THERAPEUTICS
Industry:
Biotechnology Emergency Medicine Health Care Pharmaceutical
Founded:
2000-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.melinta.com
Total Employee:
251+
Status:
Active
Contact:
(203) 624-5606
Email Addresses:
[email protected]
Total Funding:
877.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Apache
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Xeris Pharmaceuticals
Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-06-09 | Tetraphase Pharmaceuticals | Tetraphase Pharmaceuticals acquired by Melinta Therapeutics | N/A |
| 2017-11-29 | The Medicines Company - Infectious Disease Care | The Medicines Company - Infectious Disease Care acquired by Melinta Therapeutics | 270 M USD |
Investors List
CARB-X
CARB-X investment in Grant - Melinta Therapeutics
Deerfield
Deerfield investment in Post-IPO Debt - Melinta Therapeutics
Oberland Capital
Oberland Capital investment in Post-IPO Equity - Melinta Therapeutics
Malin Corporation
Malin Corporation investment in Post-IPO Equity - Melinta Therapeutics
Vatera Healthcare Partners
Vatera Healthcare Partners investment in Post-IPO Equity - Melinta Therapeutics
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Melinta Therapeutics
Falcon Flight
Falcon Flight investment in Post-IPO Equity - Melinta Therapeutics
Vatera Healthcare Partners
Vatera Healthcare Partners investment in Post-IPO Equity - Melinta Therapeutics
ABS Ventures
ABS Ventures investment in Post-IPO Equity - Melinta Therapeutics
Vox Equity Partners I
Vox Equity Partners I investment in Post-IPO Equity - Melinta Therapeutics
Key Employee Changes
Official Site Inspections
http://www.melinta.com Semrush global rank: 4.27 M Semrush visits lastest month: 2.72 K
- Host name: 4.236.191.31
- IP address: 4.236.191.31
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Melinta Therapeutics"
CORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING …
2 days ago We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph …See details»
Melinta Therapeutics - Wikipedia
Melinta Therapeutics is an American biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant …See details»
Melinta Therapeutics Announces Strategic Acquisition by
1 day ago About Melinta Therapeutics Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening …See details»
Melinta Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our …See details»
Melinta Therapeutics Improves Employee Engagement …
Sep 24, 2024 Melinta Therapeutics is an American publicly traded biopharmaceutical firm. They focus on the design and development of novel broad-spectrum antibiotics and expanding their portfolio where patients are …See details»
Melinta Therapeutics
Feb 25, 2025 Melinta Therapeutics was founded in 2013 by the healthcare investment firm, Nimbus Management. The company was originally focused on developing novel antibiotics for …See details»
Melinta and Cempra Announce Accomplished Executive …
Melinta Therapeutics, Inc., a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, and Cempra, Inc. (Nasdaq: CEMP) today …See details»
About Melinta - Melinta
At Melinta, we are committed to ensuring that everything we do to achieve our mission is rooted in the highest standards of integrity and complies with the laws and regulations that govern our industry. It is the foundation upon which we …See details»
Melinta Medical Affairs
Melinta Medical Affairs This online site is intended to provide information and resources to aid Healthcare Providers in making informed, timely, and evidence-based decisions on the use of our therapies for appropriate patients.See details»
Melinta Therapeutics Announces Strategic Acquisition by …
1 day ago Melinta has strengthened its position with global presence through ex-US partnerships and seven business development deals, including strategic partnership with BARDA to …See details»
Melinta Therapeutics, LLC Company Profile - Dun & Bradstreet
Company Description: Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. Its …See details»
Biotech CEO Sisterhood: Melinta Therapeutics CEO Christine Miller …
Interviewed by Sisterhood editorial board member Grace Colón, Christine Miller describes taking the job at Melinta after a business reorganization and in the middle of the pandemic, and …See details»
Melinta Therapeutics Announces Strategic Acquisition by …
1 day ago PARSIPPANY, N.J., August 07, 2025--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry LeadershipSee details»
Melinta Therapeutics Provides Corporate Updates
About Melinta Therapeutics Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial …See details»
Leaders Archives - Melinta
Sep 5, 2024 In 2020 he was appointed to lead the transition team to set up the medical affairs organization for the spin-off of Organon, where most recently, before joining Melinta, he acted …See details»
CorMedix Acquires Melinta in $300M Deal to Expand Infectious …
1 day ago CorMedix expands acute care presence with $300M Melinta buyout, adding 6 hospital-focused products. Deal includes $25M milestone payment potential. See full details.See details»
Melinta Therapeutics Announces Strategic Acquisition by …
1 day ago Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has …See details»
Our Impact - Melinta
Melinta’s growing portfolio represents our commitment to providing innovative therapies for acute and life-threatening illnesses. We are unparalleled in our ability to meet the unmet needs of …See details»
Melinta Medical Affairs
Melinta will not provide Grant funding to an organization in a manner that undermines the independence or mission of the organization. All requests shall be reviewed by Melinta …See details»
CorMedix to Buy Melinta Therapeutics for $300 Million - WSJ
1 day ago CorMedix has signed a deal to buy fellow biopharmaceutical company Melinta Therapeutics from healthcare-focused investment firm Deerfield Management for $300 million …See details»